Search
Search results
324 results found
Research
Research
Safety and antiviral activity of triple combination broadly neutralizing monoclonal antibody therapy against HIV-1: a phase 1 clinical trial
Julg, Boris, Kathryn E. Stephenson, Kshitig Wagh-, -Bette Korber, and Dan H. Barouch. 2022. “Safety and Antiviral Activity of Triple Combination Broadly Neutralizing Monoclonal Antibody Therapy Against HIV-1: A Phase 1 Clinical Trial”. Nature Medicine 28 (6): 1288-96.
Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua
Hallman, Mitchell, Adam Driscoll, Ryan Lubbe, and . 2020. “Lorem Ipsum Dolor Sit Amet, Consectetur Adipiscing Elit, Sed Do Eiusmod Tempor Incididunt Ut Labore et Dolore Magna Aliqua.”
Povutpat Egestas Erat Rhoncus Dapibus Senectus Fringippa.
Stone, J, P Priya, M. Wong, P Stanbrige, N Lee-Walsh, and A Li. 2020. “Povutpat Egestas Erat Rhoncus Dapibus Senectus Fringippa..”
Modeling resistance to the broadly neutralizing antibody PGT121 in people living with HIV-1
Cassidy, Tyler, Kathryn E. Stephenson, Dan H. Barouch, and Alan S. Perelson. 2024. “Modeling Resistance to the Broadly Neutralizing Antibody PGT121 in People Living With HIV-1”. PLoS Computation Biology 20.
Safety and Immunogenicity of Ad26-Vectored HIV Vaccine With Mosaic Immunogens and a Novel Mosaic Envelope Protein in HIV-Uninfected Adults: A Phase 1/2a Study
Stieh, Daniel J., Dan H. Barouch, Christy Comeaux-, -Kathryn E. Stephenson-, -Hanneke Schuitemaker, and Frank Tomaka. 2023. “Safety and Immunogenicity of Ad26-Vectored HIV Vaccine With Mosaic Immunogens and a Novel Mosaic Envelope Protein in HIV-Uninfected Adults: A Phase 1/2a Study”. Journal of Infectious Diseases 227 (8): 939-50.
Durable Humoral and Cellular Immune Responses 8 Months after Ad26.COV2.S Vaccination
Barouch, Dan H., Kathryn E. Stephenson, Jerald Sadoff-, -Johan van Hoof, and Hanneke Schuitemaker. 2021. “Durable Humoral and Cellular Immune Responses 8 Months After Ad26.COV2.S Vaccination”. New England Journal of Medicine 385 (10): 951-53.
Interim Results of a Phase 1-2a Trial of Ad26.COV2.S Covid-19 Vaccine
Sadoff, Jerald, Mathieu Le Gars, Georgi Shukarev-, -Kathryn E. Stephenson-, -Johan van Hoof, and Hanneke Schuitemaker. 2021. “Interim Results of a Phase 1-2a Trial of Ad26.COV2.S Covid-19 Vaccine”. New England Journal of Medicine 384 (19): 1824-35.